[Solved]: In the Phase 3 COMET trials, which outcome best…

In the Phase 3 COMET trials, which outcome best reflects the clinical benefit of acoltremon in patients with DED? A. No difference from vehicle in Schirmer scores through 90 daysB. Significant tear production increases within 14 days, sustained through 90 daysC. Improvements in ocular redness, with no impact on patient-reported outcomesD. Rapid tear production improvement requiring concurrent corticosteroid therapy